All recent research on the imbalance of KP metabolites during brain development show that interventions aimed at directly reducing KP metabolites or their sites of actions at critical periods may shed light on novel therapeutic strategies not only for neurodevelopmental disorders, but also to prevent the manifestation of neuropsychiatric and other CNS disorders. This evidence concerns the gene NPPA and central nervous system disorder.